Optiscan Imaging Ltd (ASX: OIL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Optiscan Imaging Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $87.71 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 835.34 million
Earnings per share -0.008
Dividend per share N/A
Year To Date Return 25.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Optiscan Imaging Ltd (ASX: OIL)
    Latest News

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    Share Market News

    Why the OptiScan (ASX:OIL) share price is rocketing 26% today

    The OptiScan Imaging Limited (ASX: OIL) share price is rocketing 26% after announcing the appointment of a experienced industry executive.

    Read more »

    Share Market News

    Why the Optiscan (ASX:OIL) share price is going gangbusters

    The Optiscan share price is flying today as the company announced the next stage of its breast cancer study.

    Read more »

    Share Market News

    Why the OptiScan (ASX:OIL) share price is climbing higher

    The Optiscan Imaging Ltd (ASX: OIL) share price is up 4.35% today after a positive announcement on a product order.

    Read more »

    woman looking up as if watching asx share price
    Share Market News

    Optiscan (ASX:OIL) share price flat on FDA update

    The Optiscan Imaging Limited (ASX: OIL) share price is flat today despite FDA advice. Let's look at what's ahead for…

    Read more »

    OIL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Optiscan Imaging Ltd

    Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation.

    OIL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 May 2024 $0.11 $0.00 0.00% 54,737 $0.11 $0.11 $0.10
    27 May 2024 $0.11 $0.00 0.00% 318,322 $0.10 $0.11 $0.10
    24 May 2024 $0.10 $0.00 0.00% 164,280 $0.11 $0.11 $0.10
    23 May 2024 $0.11 $0.00 0.00% 34,660 $0.10 $0.11 $0.10
    22 May 2024 $0.11 $0.00 0.00% 79,344 $0.11 $0.11 $0.10
    21 May 2024 $0.11 $0.01 10.20% 100,000 $0.11 $0.11 $0.11
    20 May 2024 $0.10 $-0.01 -9.09% 1,060,799 $0.11 $0.11 $0.09
    17 May 2024 $0.11 $-0.01 -8.33% 166,919 $0.12 $0.12 $0.11
    16 May 2024 $0.12 $0.00 0.00% 873,182 $0.13 $0.13 $0.12
    15 May 2024 $0.12 $0.00 0.00% 561,962 $0.13 $0.13 $0.12
    14 May 2024 $0.12 $0.00 0.00% 1,194,459 $0.12 $0.15 $0.12
    13 May 2024 $0.12 $0.02 20.41% 1,163,007 $0.10 $0.13 $0.10
    10 May 2024 $0.10 $0.01 11.11% 323,940 $0.09 $0.11 $0.09
    09 May 2024 $0.09 $-0.01 -10.53% 183,296 $0.10 $0.10 $0.09
    08 May 2024 $0.10 $0.00 0.00% 261,759 $0.09 $0.10 $0.09
    07 May 2024 $0.09 $0.01 11.90% 277,178 $0.08 $0.09 $0.08
    06 May 2024 $0.08 $0.00 0.00% 104,224 $0.08 $0.08 $0.08
    03 May 2024 $0.08 $0.00 0.00% 26,799 $0.08 $0.08 $0.08
    02 May 2024 $0.08 $0.00 0.00% 100,856 $0.08 $0.08 $0.08
    01 May 2024 $0.08 $-0.01 -11.24% 356,264 $0.10 $0.10 $0.08
    30 Apr 2024 $0.09 $0.00 0.00% 186,978 $0.09 $0.09 $0.09

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Jul 2023 Ronnie (Ron) Song Transfer 1,000,000 $80,000
    Off-market transfer.
    26 Jul 2023 Ronnie (Ron) Song Transfer 1,000,000 $80,000
    Off-market transfer.
    13 Jul 2023 Robert Cooke Issued 72,500 $5,800
    Rights issue.
    13 Jul 2023 Camile Farah Issued 2,166,667 $173,333
    Rights issue.
    13 Jul 2023 Ronnie (Ron) Song Issued 10,000,000 $80,000
    Rights issue. As per announcement on 18-07-2023

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ronnie (Ron) Song Non-Executive Director Feb 2021
    Mr Song had a 25 year business career in Australia before being headhunted in 1999 to assist in expanding a European motor vehicle franchise in Singapore. In a short time, Ron assisted in developing the franchise into a profitable business. He expanded and developed a second company in the motor vehicle industry, Premium Automobiles Pty Ltd, where he was the Managing Director for seven years before advising and developing a premier Singaporean wellness company, Fabulous Image Lifestyle, which was successfully sold to a pan-Asian operator. He is Member of Risk Committee.
    Mr Robert Cooke Non-Executive ChairmanNon-Executive Director Apr 2021
    Mr Cooke is the former Managing Director & CEO of Healthscope, one of Australia's leading private hospital, medical centre and pathology operators between 2010 and 2017. He has a 40+ year career in the health industry, his experience spans to executive leadership of publicly listed and privately owned healthcare companies, and a management of private and public hospitals in Australia, Asia and the UK. He is Member of Risk Committee.
    Ms Karen Borg Non-Executive Director Jul 2021
    Ms Borg is a experienced senior executive, who has held global leadership positions in multiple sectors, including medical devices and technology, aged care, consumer products and government. Karen's background is in commercial management, global marketing and sales and government policy. Karen was Chief Executive Officer, Catholic Healthcare Ltd and prior to this was CEO Healthdirect and the inaugural Chief Executive for Jobs for NSW. Her international healthcare experience includes President (Asia Pacific and Middle East) of ResMed Inc and several senior roles with Johnson & Johnson Medical Devices companies, including Global Vice President (based in USA). She was a NSW finalist for Telstra Businesswoman of the Year 2017.She is Chair of Risk Committee.
    Professor Camile Farah Chief Executive OfficerManaging Director May 2021
    Mr Farah is a executive, academic, researcher and author with 25 years' experience in the healthcare, biotech and medical research sectors. He is dual trained oral clinician and maxillofacial pathologist with appointments at Hollywood Private Hospital, Precision Pathology and Genomics for Life. Professor Farah is a leading Australian expert in oral cancer and precancerous pathology based on his clinical and research having published 250 clinical and scientific articles and a textbook. He is a former Dean and Chief Executive of the Oral Health Centre at the University of Western Australia. He holds an Adjunct Professor title at CQ University and an Honorary Professorial Research Fellowship at the Peter MacCallum Cancer Centre. In addition to managing his own consulting business, he is Executive Director of the Australian Centre for Oral Oncology Research & Education which undertakes cutting edge research in head and neck cancer. He serves as a non-executive director and Honorary Treasurer of the Australian and New Zealand Head and Neck Cancer Society. He is Member of Risk Committee.
    Mr Sean Gardiner Non-Executive Director Jun 2022
    Mr Gardiner is a Managing Director and Head of Private Investments at the Clermont Group. Prior to joining Clermont, Sean worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. In 2000, he joined the London office covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. In 2016, he was promoted to Head of ASEAN Research and ASEAN Equity Strategist.
    Mr Justin Mouchacca Company Secretary Dec 2016
    -
    Justin Mouchacca Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Peters Investments Pty Ltd 205,567,445 24.62%
    HSBC Custody Nominees (Australia) Limited 158,872,000 19.03%
    Ibsen Pty Ltd (Narula Family Set No.3 A/C) 38,500,000 4.61%
    Citicorp Nominees Pty Limited 36,026,006 4.31%
    Harech Pty Ltd (Porter Super Fund A/C) 18,934,491 2.27%
    Bnp Paribas Noms Pty Ltd (Drp) 18,146,343 2.17%
    Mr Chris Graham & Mrs Diane Graham (C & D Graham S/F A/C) 13,200,000 1.58%
    BNP Paribas Noms Pty Ltd Hub24 Custodial Serv Ltd (DRP A/C) 9,790,390 1.17%
    Dixson Trust Pty Limited 8,474,270 1.01%
    Camile Farah & Marie Martias (Farah & Martias Family A/C) 8,000,000 0.96%
    Sash Pty Ltd (Knezevic Super Fund A/C) 6,837,964 0.82%
    Kebin Nominees Pty Ltd 6,005,479 0.72%
    Ibsen Pty Ltd (Ibsen Superfund A/C) 5,000,000 0.60%
    Mr Alfred J Winklemeier & Mrs Christine E Winklemier 4,700,000 0.56%
    Mr Kah C Lee 4,688,888 0.56%
    Semblance Pty Ltd (Graeme Mutton Retire S/Fund) 4,470,635 0.54%
    D &K Corps Retirement Pty Ltd (D & K Corps Family A/C) 4,214,816 0.50%
    Mr Christopher J Martin 4,209,448 0.50%
    Mr Wally Knezevic 4,134,260 0.50%
    Mr Graeme L Mutton 3,490,000 0.42%

    Profile

    since

    Note